ABVX News
Archived Headlines
- French chronic disease biotech Abivax revises terms ahead of $250 million US IPO 10/18/23
- Large IPOs line up despite latest challenges 10/18/23
- French chronic disease biotech Abivax sets terms for $250 million US IPO 10/16/23
- US IPO Week Ahead: No deals scheduled for the upcoming week 10/13/23
- US IPO Weekly Recap: Holdover Adlai Nortye leads 4 IPO week as more small deals enter the pipeline 09/29/23
See more
CAR T cancer biotech CARGO Therapeutics targets a $300 million IPO, as it seeks to overcome weak trading from recent biotech listings
Another large biotech IPO has joined the calendar, seeking to buck the trend of mostly negative returns from recent listings in the industry. CARGO Therapeutics (CRGX) launched on Monday, planning to raise $300 million in what would be the...read more
Renaissance Capital's October IPO Market Update
Eleven traditional US IPOs raised a combined $2.0 billion in October, joined by one direct listing. Activity continued to fall well below the historical 10-year average (23 IPOs, $6.4B). The month's listings were led by European shoemaker...read more
US IPO Weekly Recap: Big launches and new filings keep the IPO market moving
Both the calendar and the pipeline saw some movement this past week. Two large IPOs launched, one of which also priced, and two sizable deals...read more
French chronic disease biotech Abivax prices US IPO at $11.60, the low end of the revised range
Abivax, a late-stage French biotech developing therapies for chronic inflammatory diseases, raised $236 million by offering 20.3 million shares and ADSs at $11.60, the low end of the revised range of $11.60 to $13.00. The company originally planned to offer ADSs...read more